The endothelium in lung fibrosis: a core signaling hub in disease pathogenesis?


Journal

American journal of physiology. Cell physiology
ISSN: 1522-1563
Titre abrégé: Am J Physiol Cell Physiol
Pays: United States
ID NLM: 100901225

Informations de publication

Date de publication:
01 07 2023
Historique:
medline: 12 6 2023
pubmed: 15 5 2023
entrez: 15 5 2023
Statut: ppublish

Résumé

Pulmonary fibrosis (PF) is a progressive chronic lung disease characterized by excessive deposition of extracellular matrix (ECM) and structural destruction, associated with a severe 5-year mortality rate. The onset of the disease is thought to be triggered by chronic damage to the alveolar epithelium. Since the pulmonary endothelium is an important component of the alveolar-capillary niche, it is also affected by the initial injury. In addition to ensuring proper gas exchange, the endothelium has critical functional properties, including regulation of vascular tone, inflammatory responses, coagulation, and maintenance of vascular homeostasis and integrity. Recent single-cell analyses have shown that shifts in endothelial cell (EC) subtypes occur in PF. Furthermore, the increased vascular remodeling associated with PF leads to deteriorated outcomes for patients, underscoring the importance of the vascular bed in PF. To date, the causes and consequences of endothelial and vascular involvement in lung fibrosis are poorly understood. Therefore, it is of great importance to investigate the involvement of EC and the vascular system in the pathogenesis of the disease. In this review, we will outline the current knowledge on the role of the pulmonary vasculature in PF, in terms of abnormal cellular interactions, hyperinflammation, vascular barrier disorders, and an altered basement membrane composition. Finally, we will summarize recent advances in extensive therapeutic research and discuss the significant value of novel therapies targeting the endothelium.

Identifiants

pubmed: 37184232
doi: 10.1152/ajpcell.00097.2023
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

C2-C16

Auteurs

Elisabeth Fließer (E)

Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.

Thomas Lins (T)

Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.

Johannes Lorenz Berg (JL)

Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Otto Loewi Research Center, Division of Physiology and Pathophysiology, Medical University of Graz, Graz, Austria.

Martin Kolb (M)

Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Grazyna Kwapiszewska (G)

Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Otto Loewi Research Center, Division of Physiology and Pathophysiology, Medical University of Graz, Graz, Austria.
Institute for Lung Health, Member of the German Lung Center (DZL), Cardiopulmonary Institute (CPI), Giessen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH